Table 2. Thalidomide treated patients - emphasis on predominantly sensory neuropathy and dose-dependent effects on development of a neuropathy.

Somatosensory evoked potential (SSEP), dorsal root ganglion (DRG), grams (g)

Study	Number of patients treated with thalidomide	Sensory findings	Sensory-motor findings	Noteworthy findings
Lagueny A, et al. [16]	13	13	0	Two patients with prolonged SSEP's - ? dorsal column / DRG involvement
Briana C, et al. [17]	14	7	1	No correlation between cumulative dose of thalidomide and emergence of neuropathy
Cavaletti G, at al. [18]	65	46	0	A cumulative dose greater than 20 g is related to development of a neuropathy
Chaudhry V, et al. [19]	7	7	3	Dose-dependent effect. Sural nerve biopsy demonstrating Wallerian degeneration and loss of myelinated fibers
Bastuji-Garin S, et al.  [20]	135	34	no data provided	No neuropathy for daily doses of less than 25 g daily. The risk increased with increased daily dosing